Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour

W. Van De Vrie, R. L. Marquet, A. M.M. Eggermont

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


The immunosuppressive drug cyclosporin A has been evaluated recently in phase II trials in cancer therapy as a reverter of P-glycoprotein-mediated multidrug resistance. As an immunosuppressive agent, cyclosporin A potentially can enhance tumour growth. We investigated this potency of cyclosporin A in the weakly immunogenic CC531 colon adenocarcinoma model, using the same dose that had previously been shown to intensify the antitumour activity of doxorubicin in vivo. In vitro cyclosporin A caused no growth acceleration and only in high doses was growth inhibition of CC531 cells observed. In vivo no evidence of growth enhancement was found in short-term assays but, after 4 weeks, rats treated with cyclosporin A had a significantly higher tumour load, mainly consisting of locoregional metastases. These experiments in the CC531 tumour model show that cyclosporin A, used as a reverter of multidrug resistance, may produce short-term improvement of antitumour activity but may also induce enhancement of tumour metastasis.

Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalJournal of Cancer Research and Clinical Oncology
Issue number1
Publication statusPublished - 1997
Externally publishedYes


  • Cyclosporin A
  • Growth promotion
  • Metastasis
  • Multidrug resistance


Dive into the research topics of 'Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour'. Together they form a unique fingerprint.

Cite this